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Abstract: In this paper, it is proposed that polymer-coated magnetic nanorods (MNRs) can be
used with the advantage of a double objective: first, to serve as magnetic hyperthermia agents,
and second, to be used as magnetic vehicles for the antitumor drug doxorubicin (DOX). Two different
synthetic methodologies (hydrothermal and co-precipitation) were used to obtain MNRs of maghemite
and magnetite. They were coated with poly(ethyleneimine) and poly(sodium 4-styrenesulfonate),
and loaded with DOX, using the Layer-by-Layer technique. Evidence of the polymer coating and
the drug loading was justified by ATR-FTIR and electrophoretic mobility measurements, and the
composition of the coated nanorods was obtained by a thermogravimetric analysis. The nanorods
were tested as magnetic hyperthermia agents, and it was found that they provided sufficiently large
heating rates to be used as adjuvant therapy against solid tumors. DOX loading and release were
determined by UV-visible spectroscopy, and it was found that up to 50% of the loaded drug was
released in about 5 h, although the rate of release could be regulated by simultaneous application of
hyperthermia, which acts as a sort of external release-trigger. Shape control offers another physical
property of the particles as candidates to interact with tumor cells, and particles that are not too
elongated can easily find their way through the cell membrane.
Keywords: magnetic nanorod; biocompatible polymer; drug delivery system; doxorubicin;
magnetic hyperthermia
1. Background
Magnetite (Fe3O4) and maghemite (γ-Fe2O3) nanoparticles have found pathways towards
application in the biomedical field, in both diagnosis and treatment of different diseases. In addition to
the fundamental aspects related to their magnetic properties, the ultimate reason for their use is that
they are highly biocompatible and barely or non toxic to humans. Furthermore, they are suited to be
functionalized with different compounds according to their sought application [1–4]. Particularly in
the biomedical field, when designed to be injected intravenously, the particles will face the recognition
and capture by the macrophages of the immune system [5,6], hence the need to make them biomimetic
by coating with, for instance, poly(ethylene glycol) (PEG) [7], dextran [8] or chitosan [9]. Of comparable
importance is their transformation into specific-targeting vehicles designed to approach diseased cells
and not healthy ones [10]; as examples, we can cite the conjugation with CD44 monoclonal antibodies
for specific binding to 4T1 breast cancer cells [11], and the overexpression of folate or biotin receptors
in some tumor cells, suggesting the use of folic acid or biotin on the particles for preferential (rarely,
exclusive) linkage to cancer cells. The number of possible ligands is certainly large, as has been
summarized by Loomis et al. [12].
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Many of these applications have been made possible by the variety of methods available for the
synthesis of both Fe3O4 and γ-Fe2O3 nanoparticles, ranging from “dry” methods as arc-discharge,
mechanical grinding, or laser ablation, to “wet” ones based on microemulsions [13], co-precipitation [14],
sol-gel [15] and high temperature decomposition of organic precursors [16]. Most investigations related
to the use of MNPs in the biomedical field are based on spherical (sometimes rounded, or quasi-spherical)
geometries. Non-spherical particles have been less investigated with biomedical applications in focus,
although shape effects have been pointed out in the different steps of the drug delivery process, namely,
transport in the blood vessels, particle uptake by cells, and particle toxicity [5]. The second one is
perhaps the most significant for the purposes of the present work. Nanosized drug carriers have several
intrinsic advantages over conventional drug delivery systems (DDS), such as a great loading capacity,
protection from degradation, multifunctional moieties, and controlled or sustained release, which
reduce adverse effects while enhancing the safety margin of the antitumor agents [17]. Among the
nanosized carriers, advantages have been demonstrated in the literature regarding the use of nanorods
versus spheres for drug transport and delivery applications. For example, Zhao et al. [18] have shown
that rod nanoparticles have a longer residence time in the gastrointestinal tract and a greater capacity
to overcoming rapid clearance by the immune system. As a result, this geometry appeared to favor
increased bioavailability as compared to spherical nanoparticles. In the review reported by Truong
et al. [19], studies are described which demonstrate that non-spherical shaped nanoparticles are the
next-generation drug carriers, due to their facile and versatile synthesis methodologies and their
flexibility in creating tunable sizes and adaptable surface chemistries. Other authors found that long,
elongated particles were captured by tumor cells more efficiently than short rod-like, or spherical
ones, but had a similar cytotoxicity [20,21]. Some disadvantages have also been mentioned. Thus, the
rigidity of the cell membrane might hinder its ability to engulf particles with a low curvature radius,
and hence, endocytosis of elongated particles, leaving mechanical penetration of the membrane as the
main mechanism for needle-like particles [22]. This seems to be an open problem, still claiming for
further contributions.
The systems proposed here as DDS will have an additional feature on top of their non-spherical
geometry, namely, their magnetic (superparamagnetic, in fact) nature. Smart nanocarriers, sensitive
to exogenous or endogenous stimuli, such as magnetic fields in the present case, represent an
alternative targeted drug delivery method [23]. Non-sphericity brings about shape anisotropy in
addition to magnetic (crystalline) anisotropy. The accumulation of the effects of the two sources of
anisotropy should provide the nanoparticles with larger coercivity [24], something useful for magnetic
hyperthermia, as we describe below.
The magnetic nanorods (MNRs) synthesized in this paper act as smart nanocarriers, being sensitive
to both constant or direct current (dc) and alternating (ac) magnetic fields. In the latter case, they
can be applied as magnetic hyperthermia (MH) agents. Recall that in MH, the target is to achieve,
non-invasively, a localized heating of the volume (for instance, the tumor in which the particles
have been previously injected) where the NPs are placed [25–27]. This technique has become very
popular in recent years as a promising therapeutic modality suitable to be applied in the clinic [28].
Alternating magnetic fields allow a deeper penetration in the body and a less harmful ionizing effect
than conventional radio or chemotherapy. Moreover, MH induces tumor cell death through local
temperature increase so that thermal effects can also be used as a relevant external stimulus to trigger a
drug release from drug-loaded magnetic nanocarriers [29].
In the present study, two different methodologies, namely, hydrothermal and co-precipitation, were
used to synthesize Fe3O4 and γ-Fe2O3 MNRs, both dispersible in aqueous solution. The hydrothermal
method was carried out directly in aqueous media and it had the advantage of producing a homogeneous
and well-dispersed suspension of MNRs in water using a low sintering temperature and possibly
leading to a pure crystalline phase, depending of the reaction time. Using the co-precipitation approach
for producing the maghemite nanorods, it is expected to give homogeneous and phase-pure nanorods
in a short reaction time with a narrow size distribution of particles. The magnetic nanorods (MNRs)
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prepared by both methods are coated with two ionic polymers, namely, poly(ethylene imine) (PEI),
and poly(styrene sulfonate) (PSS), using the layer-by-layer (LbL) technique [30].
The MNRs were applied to hyperthermia, but also are envisaged as thermo-responsive carriers,
with the aim of producing thermally induced drug release as a result of the alternating magnetic
stimulus. The anticancer drug used to be loaded on these MNRs was doxorubicin (DOX), whose
efficacy for different kinds of tumors has been extensively demonstrated in the literature [31–33],
and therefore, it was selected to create a potent thermo-induced triggering DDS. The procedure of
combining local heating and optimum release conditions to obtain a higher DOX release lays on the
local acidity of the tumor microenvironment [34]. Such tumor acidity offers an advantage for targeted
therapy, since it is possible to create a DDS that releases a higher amount of drug in acidic media [35,36],
mostly under the action of hyperthermia.
2. Methods
2.1. Materials
Water (Milli-Q Academic, Millipore, France) solutions of poly(sodium 4-styrenesulfonate)
(PSS, Mw = 200,000 g/mol, Sigma Aldrich, (Saint Louis, MO, USA) and poly(ethylene imine) (PEI,
Mw = 2000 g/mol, Sigma Aldrich) were prepared with respective concentrations 30 w/v % and 50 w/v %
on a monomer basis. Ethanol absolute for analysis (Ph Eur grade), sodium acetate anhydrous, and FeCl3
6H2O were from Sigma-Aldrich, and used as received. NaH2PO4 H2O was purchased from Scharlau,
(Sentmenat, Barcelona, Spain) Phosphate buffer saline tablets manufactured by Sigma-Aldrich were
reconstituted by dissolving one tablet in 200 mL water, yielding 0.01 M phosphate buffer (PBS) of pH
7.4, at 25 ◦C. Glacial acetic acid was from Spectrum (Gardena, CA, USA) and used as received.
2.2. Methods
2.2.1. Synthesis of Magnetic Nanorods
Hydrothermal magnetic nanorods (MNRs) were prepared, starting from a mixture of 0.02 M
FeCl3·6H2O (75 mL) and 0.45 mM NaH2PO4 (25 mL) solutions. The mixture was transferred to a
100 mL autoclave placed in an oven and heated for 10 days at 100 ◦C. When the reaction time was
finished, the autoclave was cooled down to room temperature and the resulting Fe2O3 NRs were
collected. In order to eliminate excess reactants, the suspension was centrifuged at 12,000 rpm and the
solids were dispersed in water. The process of cleaning was repeated three times, and the particles were
finally dried at 80 ◦C overnight. The resulting NPs (denominated H2) were found to be hematite [37],
and in order to reduce them and obtain Fe3O4 MNRs, they were placed in a tube furnace and heated at
300 ◦C during 3 h with a 30 L min−1 N2 stream previously bubbled in ethanol. This creates a reducing
hydrogen atmosphere (3Fe2O3 + H2→ 2Fe3O4 + H2O). The sample, H2M hereafter, was then cooled
down to ambient temperature.
Nanorods prepared by co-precipitation [38] were obtained by adding 20 mmol of FeCl3·6H2O
into 100 mL of deionized water containing 0.5 mL poly(ethylene imine) (PEI). The mixture was
heated at 80 ◦C under magnetic stirring for 2 h, obtaining a precipitate which was then separated
by centrifugation and washed several times with a deionized water/ethanol (50/50 v/v) mixture.
The resulting Fe2O3 NR precursors (J3) obtained was reduced to MNRs (J3M) under the hydrogen
atmosphere, as above described.
2.2.2. Surface Functionalization of MNRs
The functionalization of the MNRs was carried out using the Layer-by-Layer (LbL) technique,
or alternating adsorption of polycations and polyanions [30] on the charged surface of the nanorods.
The initial layer was prepared as follows: 2.5 mL of an MNRs aqueous suspension (6.5 mg/mL) was
adjusted to pH = 8 with 0.01 M KOH aqueous solution. 2.5 mL of PEI (dissolved at a concentration
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of 80 mg/mL) was then added to this suspension, and the mixture was sonicated with an ultrasound
probe for 15 min. The PEI-coated nanorods were then washed with distilled water three times and
pellets were collected by centrifugation at 20,000 rpm for 15 min at 25 ◦C. In order to deposit the second
layer, the washed pellet was immersed in 5 mL of a PSS aqueous solution (80 mg/mL), with 15 min
ultrasound probe stirring. The PEI-PSS coated nanorods were then washed with water several times,
centrifuged at 20,000 rpm for 15 min and dried in an oven at 70 ◦C for 24 h. Evidence of the presence of
both deposited layers was confirmed by electrophoretic mobility measurements and FTIR spectroscopy
(Jasco, Tokio, Japan).
2.2.3. Morphology and Size Distribution
The morphology of the MNRs was observed by transmission electron microscopy (TEM) using a
LIBRA 120 Plus Carl Zeiss microscope (Zeiss, Oberkochen, Germany) at an accelerating voltage of
60 kV. The samples were prepared by deposition of drops of the corresponding nanoparticle suspension
(0.01 mg/mL) over small Cu grids (3 mm diameter), and the solvent (H2O) was evaporated at room
temperature. TEM images were analyzed with J-Image software (Java, National Institute of Health
(NIH), UK) in order to calculate the particle size distribution of the dried NPs.
2.2.4. Electrophoretic Mobility
The electrophoretic mobility of the particles was measured by the PALS (Phase Analysis Light
Scattering) technique using Nano-ZS instrument from Malvern Instruments, Malvern WR14 1XZ,
UK. The suspensions must be dilute enough for this technique, and 0.1% w/v was used in all
cases. pH adjustment was carried out by dropwise addition of KOH (10 mM or 100 mM) or HNO3
(same concentrations). Repeated measurements (at least 5 runs were performed) were taken, and the
average and standard deviation were taken as representatives of the mobility of each sample.
2.2.5. X-Ray Diffraction
A crystallographic study of both kinds of nanorods was performed on a Bruker D8 Discover
diffractometer (Madison, WI, USA), using Cu-Kα. Measurements were performed in the 2θ range
4◦–53◦ at 0.02◦ steps. X-ray diffraction (XRD) patterns were compared to the COD standard data [39]
in order to confirm the crystal structure of the products.
2.2.6. Fourier Transform (FTIR) Infrared Characterization
A Jasco 6200 FT IR spectrometer (Jasco, Tokio, Japan) was used in the Attenuated Total Reflection
(ATR) mode for obtaining the IR spectra of the particles and their coatings. The wavenumber range
was 400–4000 cm−1, and the spectra were obtained at room temperature with 4 cm−1 resolution.
2.2.7. Thermogravimetric Analysis
A Shimadzu TGA 50 H (Shimadzu Corporation, Tokyo, Japan) thermogravimetric analyzer
(temperature range: ambient to 1500 ◦C; sensitivity of mass loss 1 µg) was used for the evaluation of
the organic vs inorganic mass fraction of the particles. The temperature was raised up to 900 ◦C at a
rate of 10 ◦C/min in a nitrogen atmosphere (50 mL/min N2 flow).
2.2.8. Magnetic Hyperthermia (MH) Response
The magnetic hyperthermia behavior was determined in a homemade alternating current generator
previously described by the authors in references [16,40–42]. Briefly, the samples were placed in 2-mL
screw vials located in the center of the coil (dimensions of the coil: 20 mm diameter and 45 mm
length; number of turns: 8) and insulated from it by means of a styrofoam container. The coil was
made of 6 mm refrigerated copper tube connected to an oscillator, in parallel with different capacitor
combinations so that the current frequencies could be selected out of 185, 206, 236 and 285 kHz, with 7
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A maximum current, and 16.2 kA/m maximum field (or magnetic field induction up to 20.3 mT in air).
The field was measured in the center of the coil with a NanoScience Laboratories Ltd. (Staffordshire,
UK) magnetic field probe.
Upon switching on the field, the samples increased their temperature at a rate dT/dt, determined
by means of an optical-fiber thermometer (Optocon AG, Dresden, Germany). The initial temperature
selected for the sample was the physiological one, 37 ◦C (this was also the temperature of the pumped
refrigerating water), and the concentration of particles in the vial was 10 mg/mL in all cases. With this
information, it was possible to evaluate the Specific Absorption Rate (SAR), which was obtained using







where C is the volume heat capacity of the sample (CH2O = 4185 J/LK), vs is the sample volume (0.5 mL
in the reported experiments), and m is the mass of magnetic solids in the sample (5 mg). The origin of
the heating is briefly revised in the Supplementary Materials.
2.2.9. Doxorubicin Loading and Release
DOX was incorporated onto both kinds of MNRs by dispersing them in an aqueous solution
of the drug. An amount of 1 mL of DOX solution in PBS (200 µM) was mixed with 10 mg of dried
functionalized magnetic nanorods and this mixture was stirred for 18 h at 25 ◦C. DOX-nanorods were
then magnetically decanted, washed 3 times with distilled water and freeze-dried. Supernatants were
used to determine the non-adsorbed amount of DOX: for that purpose, their optical absorbance at 489 nm
was measured in a Jenway 6705 (Cole-Parmer Ltd., Staffordshire, UK) UV–Vis spectrophotometer.
Using a calibration line (absorbance vs DOX known concentration), the drug concentration could be
obtained by interpolation. The same instrument was used for calculating the amount of DOX desorbed.
In this case, 20 mg of the drug-loaded particles was dispersed in a 5 mL volume of the PBS buffer,
and kept under agitation. At a given time, the magnetic NPs were decanted by application of a 500 mT
permanent magnet, and 0.5 mL of the supernatant was pipetted off, and its absorbance measured after
centrifugation at 20,000 rpm for 30 min (in order to get rid of any small amount of MNPs remaining
after magnetic decantation): this allowed us to know the amount of DOX released until that time.
The volume of the suspension was replenished by adding 0.5 mL PBS and the process continued until
the next extraction.
The release study was carried out both in the absence of magnetic field (keeping, in this case,
the temperature at 43 ◦C with a thermostatting bath), and with the AC magnetic field applied. In the
latter experiments, two different pHs were tested, and the magnetic field strength (the current through
the coil) was controlled in order to ensure a constant temperature of 43.0 ± 0.5 ◦C.
3. Results and Discussion
3.1. Morphology and Particle Size Distribution
Well-defined MNRs were obtained with both synthesis methods (hydrothermal –H2M- and
co-precipitation –J3M). In the case of hydrothermal synthesis, the analysis reported by Ocaña et al. [43]
confirms that phosphate ions are ultimately responsible for the spheroidal shape, as they adsorb
on planes parallel to the c-axis of growing hematite nanocrystals, facilitating their growth only in
the c-direction, this providing the anisotropic shape. When the co-precipitation method was used,
advantage was taken of the role of PEI as capping agent in the growth of β-FeOOH nuclei. According
to Mohapatra et al. [38] and Mozo et al. [44], PEI adsorbs onto (200) planes of the growing nanocrystals,
forcing again the anisotropic growth.
Table S1 of the Supporting Information file shows how the synthesis conditions affect the MNRs
size (see also Figure S1): briefly, a longer reaction time allowed the obtaining of smaller MNRs.
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Temperature also affects the morphology and the particle size: for the same reaction time, a higher
temperature produced smaller MNRs up to 250 ◦C. Above this temperature, the rod-like shape was
lost. In the co-precipitation approach, a precipitating agent was needed to produce the magnetite or
maghemite nanorods. PEI was used for this purpose, and to control the pH of the synthesis medium,
a very important issue in achieving a homogeneous morphology and particle size distribution [45].
Depending on the amount of precipitating agent used (Table S2), it is possible to control the particle size
distribution of the MNRs (Figure S2): the higher volume of PEI used in the rod preparation produced a
shorter length of Fe2O3 NRs and a more heterogeneous particle size distribution.
Both synthetic methods started with the preparation of hematite precursors; as illustrated in
Figure 1a,e, these are homogeneous, well-dispersed, rod-shaped particles. The shape was maintained
after reduction of the precursors in the oven at 300 ◦C, yielding the desired MNRs (Figure 1b,f). Polymer
coating was also clearly observed by TEM in both MNRs (Figure 1c,g). The histograms of the particle
length distributions deduced from the TEM images reveal a mean of 64 ± 20 nm particle length for
H2M MNRs (Figure 1d), and 45 ± 11 nm for J3M (Figure 1h). In general, the hydrothermal method
requires longer reaction times to achieve particle sizes under 100 nm [46]. For our reaction conditions,
10 days were needed to get a mean particle size of 64 nm. Shorter reaction times produced larger
particle sizes (Figure S1). The co-precipitation method can be used to produce smaller particle sizes in
shorter periods of time, as shown in Figure 1.
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The synthesized MNRs were analyzed by electrophoresis in order to study their stability for 
different pHs of the medium (Figure 2). The isoelectric points (pHiep) were obtained for both MNRs 
in 1 mM NaCl solutions; their values (6.6 for H2M, and 4.5 for J3M) are in a good agreement with 
those reported in literature for magnetite [47] and maghemite [48], respectively. 
Figure 1. TEM images of the precursor hematite rods (a,e), the two kinds of ti anoroads
(MNRs) (b,f , and the polymer coated MNRs (c,g). Length istograms obtai e images
of the MNRs using J-image software are shown on panels (d,h). H2 obtained by hy rothermal method,
and J3 by co-precipitation.
3.2. Electrical Characterization: Isoelectric Point Determination, Polymer Coati g a d Its tability
The synthesiz d MNRs were an lyzed by el ctrophoresis in order t ir stability for
different pHs of the medium (Figure 2). The isoelectri points (pHiep) wer obtained for both MNRs in
1 mM NaCl solutions; their values (6.6 for H2M, and 4.5 for J3M) are in a good agreement with those
reported in literature for magnetite [47] and maghemite [48], respectively.
These studies can be considered as preliminary for evaluating the proper media conditions to
carry out the polymer coating according to the Layer-by-Layer electrostatic self-assembly (LbL-ESA)
technique. The adsorption of the first polymer layer (PEI) was carried out starting with an aqueous
MNRs suspension at pH 8, in order to ensure that the particles were negatively charged. After PEI
adsorption, the MNRs shifted their surface charge to positive, and the second polymer layer (PSS)
could be added. Electrophoretic mobility data, as shown in Table 1, provide a follow-up of the
successive stages.
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Table 1. Electrophoretic mobility of bare MNRs, and of the same particles after being coated with
polyelectrolytes as indicated. The mobility measured after contact with DOX in solution is also included.
Sample Electrophoretic Mobility (10−8 ms−1/Vm−1)
H2M −2.23 ± 0.08
H2M-PEI 2.10 ± 0.04
H2M-PEI-PSS −3.73 ± 0.13
H2M-PEI-PSS-DOX 0.79 ± 0.05
J3M −2.48 ± 0.08
J3M-PEI 0.10 ± 0.05
J3M-PEI-PSS −4.8 ± 0.3
J3M-PEI-PSS-DOX −3.5 ± 0.4
In order to test the stability with time of the polymer layers in aqueous media, electrophoretic
mobility measurements were repeated for 28 days on the coated samples. Before measuring, the MNRs
were magnetically decanted, the supernatant was removed, and fresh water was used each day to
re-disperse the MNRs. As observed in Figure S3, the mobility of the two kinds of PEI/PSS-coated
particles decreased only slightly during the measurement period, indicating a very limited loss of PSS
molecules with time.
3.3. XRD Diffraction
Nine characteristic peaks of hematite (at 2θ ≈ 24.2, 33.2, 35.7, 40.9, 49.5, 54.1, 57.7, 62.5 and 64.1
degrees, Cu Kα radiation), marked by their Miller indices ((012), (104), (110), (113), (024), (116), (122/018),
(214), (300)), were observed for both precursor samples (Figure S4). After reduction, the precursors
transformed into magnetite or maghemite species, as confirmed by the fact that the angles and
intensities of the diffraction peaks are consistent with the standard pattern for COD 9009782 (hematite)
for both precursors, and COD 9006317 (maghemite) and COD 9010939 (magnetite), for reduced J3M
and H2M nanorods [39], respectively. The samples show broad peaks, indicating that the nanorods
are polycristalline.
3.4. Thermogravimetric Analysis
A thermogravimetric analysis was used for the evaluation of the thermal stability of the magnetic
particles, as well as to check the polymer/magnetite weight ratio and the polymer components. Figure 3
shows the weight loss of both MNRs before and after polymer coating. Taking into account the
inorganic residue of the MNRs before coating (95%), it is possible to calculate the percentage of
inorganic component versus the organic ones in the thermogram of the layered MNRs, obtaining a
92% inorganic component (maghemite) for J3M MNRs and 89.6% magnetite for H2M MNRs.
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The first derivative of the weight loss curve of the polymer-coated MNRs shows the degradation
temperature of the different components. The first weight loss below 100 ◦C belongs to water molecules
entrapped in the polymer matrix coating the MNRs. The second peak at 273 ◦C, corresponds to the
degradation of the PSS [49], while the third peak at 437 ◦C can be attributed to the degradation of
PEI [50]. Finally, the weight loss between 600 and 800 ◦C was due to the reduction of magnetite to α-Fe
and FeO species (in the case of J3M maghemite degrades first to magnetite [51]). Once the degradation
peaks were identified in the thermogram, it was possible to quantify the percentage of the organic
components for both MNRs. Details are provided in Table 2. In both MNRs the magnetic component
was nearly 90%, which secures the optimal response under a magnetic field and therefore, a proper




Figure 3. Thermograms of uncoated (a) and coated (b) magnetic MNRs.
Table 2. Mass percentage of the components (inorganic and polymeric) of bare and coated magnetic
NRs calculated from TGA curves.
H2M-PEI-PSS % Weight J3M-PEI-PSS % Weight
Fe3O4 89.6 γ-Fe2O3 92.0
PEI 5.1 PEI 3.2
PSS 5.3 PSS 4.8
3.5. ATR-FTIR Characterization
The ATR-FTIR spectra are shown in the Figure S5, and they show evidence of the polymer coating
on both kinds of particles. The PEI characteristic bands (Figure S5) at 1043–1355 cm−1 correspond to
stretching vibrational modes of C–N bonds, those at 1720–1780 cm−1 belong to the imide group, 5 and
at 3100–3300 cm−1, we can observe the vibration of the N–H bonds [4]. PSS shows its characteristic
peaks at 600–900 cm−1 (C–S) and 1050–1200 cm−1 (S=O) due to the sulfonate group, and at 1600–1680
cm−1 due to the aromatic ring (C=C). Both polymers are in aqueous solution, hence the intense band
at 3200–3500 cm−1, corresponding to the OH groups of water. Magnetite and maghemite show their
Fe–O vibration peaks at 629 cm−1.
3.6. Magnetic Hyperthermia
As mentioned, the hyperthermia response, as measured by the SAR value, depends on the
morphology and anisotropy of the particles. Other authors have demonstrated, for example, that cubic
or octopods iron oxide nanoparticles had superior magnetic heating efficiency as compared to spherical
particles of similar sizes [52–54], especially in the high field region. It has also been reported that the
formation of spherical particle chains increased the SAR over that reached by individual separated
particles [55]. Figure 4 shows the temperature-time plots of both bare and coated magnetic MNRs at
different frequencies of the alternating current (ac) field, as well as the SAR and ILP reached with each
type of particles. As observed, longer MNRs (64 nm, H2M) showed higher SAR than MNRs of 40 nm
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length (J3M) (Table 3). ILP values in both magnetic MNRs were larger than in most spherical magnetic
nanoparticles, with a similar particle size, described in literature [41,56,57]; this is the advantage of
using rod-shaped magnetic nanoparticles in hyperthermia with a higher shape and magnetic anisotropy
and therefore, a greater coercivity. In fact, the larger SAR values found for non-spherical particles have
been found for geometries other than spheroidal. A comparison recently carried out by Nikitin et
al. [58] between the hyperthermia performance of spherical, cubic and rod-like MNPs demonstrated
that the latter yield the highest value, with SAR above 800 W/g, which the authors assigned to the
high coercivity of the particles, and Albarqi et al. [59] used hexagonal MnCo iron oxides capable of
reaching SAR values in excess of 500 W/g for hyperthermia treatment of ovarian cancer cells. All these
results point to the extreme interest of non-spherical MNPs in hyperthermia, and the contributions of
Noh et al. [60] regarding the basis of nanoscale magnetism indicate that the increased coercivity of the
MNPs was on the basis of this extremely good performance.
However, when magnetic MNRs were coated, the shorter MNRs showed a slightly higher
hyperthermia response, with a mean SAR, between 10 and 25 W/g and an ILP of 0.29 nHm2/kg for
J3M-PEI-PSS, as compared to 6–13 W/g and 0.24 nHm2/kg for H2M-PEI-PSS (Table 3). As expected,
the reduction in the relative mass of magnetic material in the coated rods led to a decrease in heat
release per unit mass of particles. Nevertheless, this decrease was smaller in J3M MNRs, probably due
to the smaller particle size of these particles and the thinner polymer coating on them, as determined
by composition analysis obtained by TGA characterization. In general, SAR and ILP values are




Figure 4. Hyperthermia response tests: temperature-time curves of uncoated and coated magnetic
MNRs (a–d). SAR and ILP values vs. frequency (e,f).
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Table 3. SAR and ILP values calculated for un-coated and coated magnetic MNRs.
Sample SAR (W/g) ILP (nHm2/kg)
H2M 26–43 1.12 ± 0.06
H2M-PEI-PSS 6–13 0.24 ± 0.04
J3M 15–26 0.52 ± 0.08
J3M-PEI-PSS 10–25 0.29 ± 0.05
3.7. Doxorubicin Loading and Release
The adsorption of DOX on the MNRs was qualitatively evidenced by electrophoretic mobility
data, as depicted in Table 1. A FTIR analysis was also applied to confirm the loading. Figure 5
shows the FTIR spectra of the coated magnetic MNRs modified after the adsorption of doxorrubicin
and compared to that of pure DOX and coated particles. The adsorption of DOX onto the coated
magnetic MNRs resulted in a change of the FTIR spectrum, as shown in Figure 5a: additional bands
that can be ascribed to doxorubicin appeared at 990–1120 cm−1 and 1210–1290 cm−1. Methylene
stretching vibrations at 2850 and 2910 cm−1, methyl stretching and aromatic C−H stretching at 2940
and 3030 cm−1, as well as amine stretching at 3340 cm−1 (DOX) were merged into a very broad band
in the 2800−3600 cm−1 range, most probably due to the intermolecular hydrogen bonds between the
polymers and adsorbed doxorubicin.
Pharmaceutics 2019, 11, x FOR PEER REVIEW 11 of 16 
 
the 2800−3600 cm−1 range, most probably due to the intermolecular hydrogen bonds between the 
polymers and adsorbed doxorubicin. 
 
Figure 5. FTIR spectra of the DOX-loaded (a,b) and polyelectrolyte coated (c,d) magnetic MNRs and 
of pure DOX (e). 
However, neither electrophoresis nor FTIR allow the quantification of the percentage of 
adsorbed drug. For this purpose, UV–visible spectroscopy was used, as it made it possible to 
quantify the amount of drug adsorbed and released as a function of time. Table 4 shows the results 
of DOX loading for both magnetic MNRs. It can be observed that the amount of adsorbed drug was 
higher for the smaller MNRs (J3M-PEI-PSS) as compared to the larger (H2M-PEI-PSS) ones. This 
may be a result of the larger surface area of the former particles, but additionally, the J3M-PEI-PSS 
particles have a larger negative surface charge (Table 1), and this favors adsorption of the positive 
DOX molecules by electrostatic interaction. 
Table 4. Quantification of the doxorubicin adsorbed onto the coated magnetic MNRs (drug loading). 
Sample % Adsorbed DOX µg DOX/mg MNRs 
H2M-PEI-PSS 64.4 7.0 
J3M-PEI-PSS 84.1 20.0 
Recall that the DOX molecule shows an amino group in its structure, which presents a pKa of 
9.93 [61]. When this drug is in salt form (DOX-HCl) it can be dissolved in water, and it dissociates 
into doxorubicin, H+, and Cl−. The primary amine of doxorubicin is then positively charged at acidic 
pH, which makes the molecule more soluble. However, the carbonyl group of C13 in DOX can be 
negatively charged at pH > 8, and therefore, the total surface charge of DOX at pH 7.4 is slightly 
positive or close to neutral. Then, at physiological pH, the release of DOX is slow due to the limited 
ionization of the drug, which makes it less water soluble. Nevertheless, at acid pH (pH = 5.5), DOX is 
highly positively charged and therefore, very water soluble. For this reason, the DOX release is 
expected to be faster at acid than at physiological pH, as was proven in the release test (see below). 
The release of the drug was investigated in three experimental conditions: maintaining the 
solution at 43–44 °C, releasing while applying hyperthermia at pH 5.5, and repeating the latter 
Figure 5. FTIR spectra of the DOX-loaded (a,b) and polyelectrolyte coated (c,d) magnetic MNRs and of
pure DOX (e).
However, neither electrophoresis nor FTIR allow the quantification of the percentage of adsorbed
drug. For this purpose, UV–visible spectroscopy was used, as it made it possible to quantify the
amount of drug adsorbed and released as a function of time. Table 4 shows the results of DOX loading
for both magnetic MNRs. It can be observed that the amount of adsorbed drug was higher for the
smaller MNRs (J3M-PEI-PSS) as compared to the larger (H2M-PEI-PSS) ones. This may be a result
of the larg r surface area of the former particles, but additionally, the J3M-PEI-PSS particles have a
larger negative surface charge (Table 1), and this favors adsorption of the positive DOX molecules by
electrostatic interaction.
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Table 4. Quantification of the doxorubicin adsorbed onto the coated magnetic MNRs (drug loading).
Sample % Adsorbed DOX µg DOX/mg MNRs
H2M-PEI-PSS 64.4 7.0
J3M-PEI-PSS 84.1 20.0
Recall that the DOX molecule shows an amino group in its structure, which presents a pKa of
9.93 [61]. When this drug is in salt form (DOX-HCl) it can be dissolved in water, and it dissociates into
doxorubicin, H+, and Cl−. The primary amine of doxorubicin is then positively charged at acidic pH,
which makes the molecule more soluble. However, the carbonyl group of C13 in DOX can be negatively
charged at pH > 8, and therefore, the total surface charge of DOX at pH 7.4 is slightly positive or close
to neutral. Then, at physiological pH, the release of DOX is slow due to the limited ionization of the
drug, which makes it less water soluble. Nevertheless, at acid pH (pH = 5.5), DOX is highly positively
charged and therefore, very water soluble. For this reason, the DOX release is expected to be faster at
acid than at physiological pH, as was proven in the release test (see below).
The release of the drug was investigated in three experimental conditions: maintaining the solution
at 43–44 ◦C, releasing while applying hyperthermia at pH 5.5, and repeating the latter procedure at
pH 7.4. In these cases, the MNRS loaded with DOX were exposed to the magnetic field until they
reached the desired temperature of 43–44 ◦C, typical for hyperthermia-induced apoptosis. After a
rapid increase in temperature, the system was stabilized at 43–44 ◦C by controlling the ac current
applied to the coil.
As can be observed in Figure 6, the amount of drug released after 4 h at 43◦C without the ac field
applied was 10% for H2M-PEI-PSS MNRs and 8% for J3M-PEI-PSS MNRs. These percentages of DOX
release did not increase markedly after 120 h, probably due to the poor DOX solubility at physiological
pH. Conversely, during application of the ac field (hyperthermia-triggered release), the DOX released
was increased to a great extent, reaching 25% and 40% of DOX released for H2M-PEI-PSS MNRs and
J3M-PEI-PSS MNRs, respectively, at physiological pH after the first 4 h. The response of release to
hyperthermia was also analyzed at acid pH (pH 5.5), where the DOX shows better water solubility.
Here, the release of the drug achieved 50% after 4 h for both MNR systems. These results prove that the
application of an ac field significantly improved the release of DOX, allowing for a significant release
of this drug in a local area where the magnetic field was applied.
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Figure 6. DOX release at 43 ◦C without the application of AC field (squares) (a), under AC field (b) at
pH 7.4 (circles), and under AC field at pH 5.5 (diamonds), from both coated magnetic nanorods.
The faster release with hyperthermia in acid environment is obviously beneficial for cancer
treatment. Although the tumor pH may vary according to the tumor area, and the intracellular pH
cells within healthy tissues and tumors is similar, tumors exhibit a lower extracellular pH than normal
tissues—between 6.0 and 7.0—whereas, in normal tissues and blood, the extracellular pH of is around
7.4 [62]. The low extracellular tumor pH mostly arises from the high glycolysis rate in hypoxic cancer
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cells. Thus, in the low pH extracellular environment of the cancer cells, DOX can diffuse more easily
through the cell membrane and this enhances its role as an anticancer drug.
4. Conclusions
Well defined magnetic nanorods (MNRs) were obtained by two synthesis methods, namely,
hydrothermal and co-precipitation. The latter allows for the preparation of smaller particle sizes in
shorter reaction times. The obtained MNRs (magnetite and maghemite) were successfully coated
with ionic polymers and loaded with doxorubicin (DOX) using the well-established LbL technique.
High drug loading was achieved for both MNRs, which was thus demonstrated to be excellent drug
carrier candidates, with the additional advantage of being suitable for remote manipulation when
exposed to external magnetic fields. Furthermore, the two formulations, both before and after coating,
showed significant hyperthermia when subjected to alternating magnetic fields with a frequency in the
100–200 kHz range and a field strength of 10–20 kA/m. Not only can this magnetic hyperthermia be
applied to tumor treatment by controlling the temperature elevation of the tumoral tissue, but it was
found that hyperthermia increased the rate of DOX release from the drug-loaded particles, especially
in acidic media, where 50% of the loaded DOX could be released from both types of nano-rods particles
in less than 4 h.
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